

8. ~~(amended)~~ [Prostaglandins E as described] An anti-ulcer composition as in claim 58, wherein R<sub>4</sub> and R<sub>5</sub> are halogen atoms.

9. ~~(amended)~~ [Prostaglandins E as described] An anti-ulcer composition as in claim 58, wherein R<sub>4</sub> and/or R<sub>5</sub> is a fluorine atom.

10. ~~(amended)~~ [Prostaglandins E as described] An anti-ulcer composition as in claim 58, wherein R<sub>4</sub> or R<sub>5</sub> is a methyl group.

11. ~~(amended)~~ [Prostaglandins E as described] An anti-ulcer composition as in claim 58, [being] wherein the prostaglandin E is 13,14-dihydro-15-keto-PGE having one or more fluorine atom(s) on 16-position or alkyl ester thereof.

12. ~~(amended)~~ [Prostaglandins E as described] An anti-ulcer composition as in claim 58, [being] wherein the prostaglandin E is 13,14-dihydro-6,15-diketo-16R,S-fluoro-PGE, or alkyl ester thereof.

REMARKS

Responsive to the rejection under 35 U.S.C. §112, first and second paragraphs, claims 53-57 have been amended to depend from claim 52. Additionally, claims 60-63 have been amended to refer to the anti-ulcer composition of claim 58.

AMENDMENT UNDER 37 C.F.R. §1.115  
U.S. Appln. No. 07/925,220

Entry of the amendments and withdrawal of the foregoing  
rejection is respectfully requested.

There are no outstanding prior art rejections.

Early allowance of claims 52-64 is requested.

Respectfully submitted,

  
\_\_\_\_\_  
Abraham J. Rosner  
Reg. No. 33,276

SUGHRUE, MION, ZINN, MACPEAK  
& SEAS  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037  
Phone: (202) 293-7060  
FAX: (202) 293-7860

Date: June 11, 1993